Back

Comparative effectiveness of dabigatran, rivaroxaban, and edoxaban on cardiac and renal outcomes in Asian patients with atrial fibrillation: a propensity score-weighted analysis

30 August 2025 (12:30 - 13:15)
Organised by: Logo
Congress Presentation Part of: New perspectives in cardiology (2) - Drivers and modifiers of atrial fibrillation Oral Anticoagulation ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Jong-Shiuan Yeh

Wang-Fang Medical Center, Taipei (Taiwan)

8 More presentations in this session

Presentation thumbnail
Presentation thumbnail
Doctor P. Festa (Rome, IT)
Abstract Slides Video
Presentation thumbnail
Doctor P. Haemmerle (Basel, CH)
Abstract Slides Video
Presentation thumbnail
Assistant Professor K. Lee (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Doctor M. Lehto (Helsinki, FI)
Abstract

Access the full session

Session thumbnail
New perspectives in cardiology (2) - Drivers and modifiers of atrial fibrillation

The Event

Event poster

ESC Congress 2025

30 August 2025 12:30 CET
You may be interested in
thumbnail
Congress Presentation
Clinical outcomes in >10,000 Asian vs >61,000 Non-Asian race patients with AF randomized to Warfarin vs DOACs: a patient-level meta-analyses from COMBINE AF
thumbnail
Congress Presentation
Impact of renal impairment and other high bleeding risk factors on clinical outcomes among Asian patients with atrial fibrillation on edoxaban: a post hoc analysis of the ETNA-AF program
thumbnail
Congress Session
Atrial fibrillation management and outcomes in high-risk atrial fibrillation populations

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources